Physician profile
Cheryle L Levoy
NPI 1639554066
$1,910.49
in general payments reported to CMS, 2019-2025
18 companies · $93.89 in 2025
The $93.89 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $587 · 2022: $311 · 2023: $528 · 2024: $391 · 2025: $93.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $508.44 | 2021-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $315.00 | 2021-2023 | |
| Lilly USA, LLC | $144.78 | 2021-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $118.30 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $116.38 | 2021-2024 | Breztri, Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $111.26 | 2023-2025 | Voquezna |
| Corcept Therapeutics | $111.00 | 2023-2025 | Korlym |
| Pfizer INC. | $110.32 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.91 | 2023-2024 | Trulance, Xifaxan |
| Janssen Pharmaceuticals, INC | $54.04 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.44 | 2021-2024 | Ofev |
| Biohaven Pharmaceutical Holding Company LTD. | $48.29 | 2022 | |
| Glaxosmithkline, LLC. | $40.78 | 2021 | |
| Abbott Laboratories | $33.74 | 2021-2023 | Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $31.21 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $23.20 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.64 | 2024 | Caplyta |
| Philips North America LLC | $14.76 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryle Levoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.